ADMA Biologics (NASDAQ:ADMA) Stock

ADMA Biologics

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Beijing,,China,-,June,4,,2023:,Keysight,Sign,Is,Seen

News

Markets

Media

Trading Ideas

ADMA

KEYS

NVCR

On CNBC&#39;s &#34;Mad Money Lightning Round,&#34; Jim Cramer recommended buying Keysight Technologies calling it a &#34;Terrific business.&#34;

Jim Cramer Likes This Tech Stock: &#39;Terrific Business, Niche Business&#39;

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

SANA


Despite the strength of the economy overall, 2024 was a challenging year for the biotech industry. The high cost of borrowing—particularly prior to the Fed&#39;s first rate cut in several years in

There May Still Be Time to Get in on These 3 Trending Biotechs

ADMA Biologics Inc

Disclosed in a recent SEC filing on February 4, Kestenberg-Messina, COO and SVP at ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>), made a noteworthy transaction involving the exercise of company stock options.
What Happened: Kestenberg-Messina, COO and SVP at ADMA Biologics, exercised stock options for 5,000 shares of ADMA stock. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000114036125002926//Archives/edgar/data/1368514/000114036125002926/0001140361-25-002926-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The exercise price of the options was $10.8 per share.
Currently, ADMA Biologics shares are trading up 0.24%, priced at $16.51 during Tuesday's morning. This values Kestenberg-Messina's 5,000 shares at $28,550.
<h3>About ADMA Biologics</h3>
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
<h3>Unraveling the Financial Story of ADMA Biologics</h3>
Revenue Growth: Over the 3 months period, ADMA Biologics showcased positive performance, achieving a revenue growth rate of 78.13% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 49.78%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): ADMA Biologics's EPS is below the industry average. The company faced challenges with a current EPS of 0.15. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.48, caution is advised due to increased financial risk.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 61.0 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 10.23 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): ADMA Biologics's EV/EBITDA ratio of 39.64 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001368514">Check Out The Full List Of ADMA Biologics's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Engaging In Insider Activity, Kaitlin M. Kestenberg-Messina At ADMA Biologics Exercises Options Worth $28K

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said he likes Keysight Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) and recommended buying the same. &#8220;Terrific business, <a href="https://www.benzinga.com/quote/KEYS/analyst-ratings">niche business,&#8221; he added</a>.
Supporting his view, JPMorgan analyst Samik Chatterjee, on Dec. 16, upgraded Keysight from Neutral to Overweight and announced a $200 price target.
<h3 class="wp-block-heading">Shares Views On These Health Care Names</h3>
Cramer recommended to wait for ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) to come down before pulling the trigger. &#8220;I don't have a catalyst,&#8221; he noted.
The company's stock has jumped more than 206% over the past year.
&#8220;I just think that they should be making money,&#8221; Cramer said when asked about NovoCure Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>). &#8220;Let's see some money made by Novocure and then we can get behind it.&#8221;
Novocure, meanwhile, on Jan. 13, reported preliminary net revenues for FY2024 of $605.2 million and preliminary net revenues of $161.3 million for the fourth quarter.
<h3 class="wp-block-heading">Other Stocks In Focus</h3>
When asked about Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), he said, &#8220;I do not want to get in the way of the Palantir buzz saw because that's very close to Elon Musk.&#8221;
Lockheed Martin, meanwhile, on Jan. 28, reported mixed fourth-quarter 2024 results. The company reported a net sales decline of 1.3% year-over-year to $18.622 billion, missing the consensus of $18.91 billion. LMT reported Adjusted EPS of $7.67, beating the consensus of $6.64.
Price Action:
<ul>
<li>Lockheed Martin shares fell 0.7% to settle at $454.36 on Wednesday.</li>
<li>ADMA Biologics shares gained 1.3% to close at $16.38 during the session.</li>
<li>Novocure shares fell 0.2% to settle at $25.52 on Wednesday.</li>
<li>Keysight shares rose 0.2% to settle at $168.33 on Wednesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43300989/jim-cramer-this-industrial-stock-is-absolutely-terrific-first-solar-is-very-inexpensive">Jim Cramer: This Industrial Stock Is &#8216;Absolutely Terrific&#8217;, First Solar Is &#8216;Very Inexpensive&#8217;</a></li>
</ul>
Image: Shutterstock

Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'

ADMA Biologics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NYSE">ADMA</a>) short percent of float has risen 11.89% since its last report. The company recently reported that it has 13.62 million shares sold short, which is 5.93% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>ADMA Biologics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737573317_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ADMA Biologics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing ADMA Biologics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ADMA Biologics's peer group average for short interest as a percentage of float is 13.65%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into ADMA Biologics's Recent Short Interest

WIIM

ADMA Biologics shares are trading lower. The company reported preliminary FY24 revenue results.

<ul>
<li>FY 2024 Preliminary Unaudited Total Revenue of Approximately $417-425 Million, Exceeding Previous Guidance of $415 Million</li>
<li>YE 2024 Total Cash Grew to More than $100 Million, an Increase of Approximately $45 Million Q-o-Q, Notwithstanding $30 Million of Debt Organically Discharged During 4Q 2024</li>
<li>Newly Executed High Titer Plasma Supply Contracts Expected to Provide Foundation for Durable ASCENIV Revenue Growth Through Late 2030s</li>
<li>PAS Submitted to the FDA for Approval of Innovative Yield Enhancement Production Process; Potential Regulatory Approval Anticipated Mid-2025</li>
<li>FY 2025 and 2026 Total Revenue Guidance Expected to Exceed $485 Million and $600 Million, Respectively</li>
<li>FY 2025 and 2026 Net Income Expected to Exceed $170 Million and $230 Million, Respectively</li>
<li>FY 2025 and 2026 Adjusted EBITDA(1) Expected to Exceed $220 Million and $300 Million, Respectively</li>
<li>ADMA Anticipates Generating Greater Than $1 Billion in Total Annual Revenue Prior to 2030, More Than Doubling the Current 2025 Revenue Forecast</li>
</ul>

ADMA Reports 2024 Preliminary Revenue Of $ $417M-425M ($422.39M Est.) With With Over $100M Cash, Projects FY 2025 Revenue Over $485M And FY 2026 Above $600M

ADMA Biologics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NYSE">ADMA</a>) short percent of float has fallen 5.69% since its last report. The company recently reported that it has 12.18 million shares sold short, which is 5.3% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.6 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>ADMA Biologics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735590622_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ADMA Biologics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing ADMA Biologics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ADMA Biologics's peer group average for short interest as a percentage of float is 14.24%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About ADMA Biologics?

ADMA Biologics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NYSE">ADMA</a>) short percent of float has fallen 6.34% since its last report. The company recently reported that it has 14.24 million shares sold short, which is 6.2% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>ADMA Biologics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733423416_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ADMA Biologics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing ADMA Biologics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ADMA Biologics's peer group average for short interest as a percentage of float is 13.57%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into ADMA Biologics's Recent Short Interest

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$20.00</td>
<td>$127.4K</td>
<td>2.2K</td>
<td>5.0K</td>
</tr>
<tr>
<td>NMRA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.50</td>
<td>$86.5K</td>
<td>4.5K</td>
<td>827</td>
</tr>
<tr>
<td>SRRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$40.00</td>
<td>$27.7K</td>
<td>3.2K</td>
<td>805</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$105.00</td>
<td>$28.5K</td>
<td>901</td>
<td>558</td>
</tr>
<tr>
<td>RVMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$55.00</td>
<td>$55.4K</td>
<td>704</td>
<td>461</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$285.00</td>
<td>$31.0K</td>
<td>1.1K</td>
<td>439</td>
</tr>
<tr>
<td>BSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/13/24</td>
<td>$91.00</td>
<td>$49.3K</td>
<td>28</td>
<td>413</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$200.00</td>
<td>$108.0K</td>
<td>280</td>
<td>212</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$25.00</td>
<td>$109.2K</td>
<td>365</td>
<td>105</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.50</td>
<td>$25.3K</td>
<td>11.2K</td>
<td>66</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For ADMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>), we notice a call option trade that happens to be bullish, expiring in 18 day(s) on December 20, 2024. This event was a transfer of 1499 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $127.4K, with a price of $85.0 per contract. There were 2293 open contracts at this strike prior to today, and today 5072 contract(s) were bought and sold. 
• For NMRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>), we notice a put option sweep that happens to be bullish, expiring in 46 day(s) on January 17, 2025. This event was a transfer of 309 contract(s) at a $7.50 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $86.5K, with a price of $280.0 per contract. There were 4550 open contracts at this strike prior to today, and today 827 contract(s) were bought and sold. 
• Regarding SRRK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>), we observe a call option trade with bearish sentiment. It expires in 46 day(s) on January 17, 2025. Parties traded 99 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $27.7K, with a price of $280.0 per contract. There were 3264 open contracts at this strike prior to today, and today 805 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a put option sweep with bullish sentiment. It expires in 4 day(s) on December 6, 2024. Parties traded 250 contract(s) at a $105.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $28.5K, with a price of $114.0 per contract. There were 901 open contracts at this strike prior to today, and today 558 contract(s) were bought and sold. 
• For RVMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>), we notice a call option sweep that happens to be bearish, expiring in 18 day(s) on December 20, 2024. This event was a transfer of 426 contract(s) at a $55.00 strike. This particular call needed to be split into 45 different trades to become filled. The total cost received by the writing party (or parties) was $55.4K, with a price of $135.0 per contract. There were 704 open contracts at this strike prior to today, and today 461 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option trade with bullish sentiment. It expires in 18 day(s) on December 20, 2024. Parties traded 100 contract(s) at a $285.00 strike. The total cost received by the writing party (or parties) was $31.0K, with a price of $310.0 per contract. There were 1197 open contracts at this strike prior to today, and today 439 contract(s) were bought and sold. 
• For BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we notice a call option sweep that happens to be bullish, expiring in 11 day(s) on December 13, 2024. This event was a transfer of 411 contract(s) at a $91.00 strike. This particular call needed to be split into 48 different trades to become filled. The total cost received by the writing party (or parties) was $49.3K, with a price of $120.0 per contract. There were 28 open contracts at this strike prior to today, and today 413 contract(s) were bought and sold. 
• Regarding BIIB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), we observe a call option trade with bearish sentiment. It expires in 136 day(s) on April 17, 2025. Parties traded 200 contract(s) at a $200.00 strike. The total cost received by the writing party (or parties) was $108.0K, with a price of $540.0 per contract. There were 280 open contracts at this strike prior to today, and today 212 contract(s) were bought and sold. 
• Regarding SAVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), we observe a put option trade with bearish sentiment. It expires in 200 day(s) on June 20, 2025. Parties traded 50 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $109.2K, with a price of $2185.0 per contract. There were 365 open contracts at this strike prior to today, and today 105 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 410 day(s) on January 16, 2026. Parties traded 54 contract(s) at a $22.50 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $470.0 per contract. There were 11285 open contracts at this strike prior to today, and today 66 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMGN

BIIB

NMRA

RVMD

SAVA

SRRK

10 Health Care Stocks With Whale Alerts In Today's Session

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) with a Buy and raises the price target from $18 to $26.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $26

Raymond James analyst Elliot Wilbur maintains ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) with a Strong Buy and raises the price target from $18 to $25.

Raymond James Maintains Strong Buy on ADMA Biologics, Raises Price Target to $25

ADMA Biologics shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 and FY25 revenue guidance.

ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.11 by 36.36 percent. The company reported quarterly sales of $119.839 million which beat the analyst consensus estimate of $105.850 million by 13.22 percent. This is a 78.13 percent increase over sales of $67.275 million the same period last year.

Earnings

Earnings Beats

ADMA Biologics Q3 2024 GAAP EPS $0.15 Beats $0.11 Estimate, Sales $119.839M Beat $105.850M Estimate

ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively.

Guidance

ADMA Biologics FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively

U.S. stocks were higher, with the Dow Jones index gaining around 450 points on Friday.
Shares of Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) rose sharply during Friday's session as the company posted stronger-than-expected results for the <a href="https://www.benzinga.com/quote/AMZN">third quarter on Thursday</a>.
Amazon reported third-quarter net sales of $158.9 billion, up 11% year-over-year. The total beat a Street consensus estimate of $157.2 billion, according to data from Benzinga Pro. The company said it sees fourth-quarter net sales to come in a range of $181.5 billion to $188.5 billion, up 7% to 11% year-over-year.
Amazon.com shares jumped 7.1% to $199.63 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Proto Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) shares jumped 31.8% to $36.10 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) gained 30% to $22.72 after the company reported better-than-expected third-quarter financial results and raised its FY24 net sales guidance above estimates.</li>
<li>Globalstar, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NYSE">GSAT</a>) jumped 25.3% to $1.3145 after the company amended its services agreement with Apple to launch an extended MSS network with new satellites and infrastructure.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) gained 19.7% to $19.52.</li>
<li>Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) rose 17.3% to $378.98 after the company reported third-quarter earnings and sales that beat analyst estimates.</li>
<li>Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) gained 16.5% to $96.73 following third-quarter results.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) climbed 15.8% to $218.37 after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates.</li>
<li>Pediatrix Medical Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) rose 15.6% to $14.26 following better-than-expected quarterly earnings.</li>
<li>ASP Isotopes Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) gained 14.2% to $7.98. ASP Isotopes announced the pricing of public offering of common stock.</li>
<li>Select Medical Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) surged 13.2% to $36.32 following better-than-expected quarterly earnings.</li>
<li>Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) gained 12% to $366.93 after the company reported better-than-expected quarterly EPS and revenues.</li>
<li>Liberty Broadband Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDA#NASDAQ">LBRDA</a>) gained 11.5% to $89.49.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) gained 9.9% to $55.56 after the company reported better-than-expected quarterly financial results and issued FY24 adjusted EPS guidance above estimates.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) rose 9.6% to $14.92.</li>
<li>MasTec, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) surged 8.2% to $133.01 after the company raised its FY2024 adjusted EPS guidance.</li>
<li>Chart Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NASDAQ">GTLS</a>) gained 8.1% to $130.46 following quarterly results.</li>
<li>Dorman Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DORM#NASDAQ">DORM</a>) gained 7.9% to $123.05 following upbeat earnings.</li>
<li>Magna International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGA#NYSE">MGA</a>) jumped 7.8% to $42.54 following third-quarter results.</li>
<li>Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) gained 7.1% to $116.21 after the company reported better-than-expected first-quarter EPS and revenues and raised its FY2025 adjusted EPS guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>

Intraday Update

Movers

AMZN

ASPI

CHTR

DORM

GSAT

GTLS

HALO

LBRDA

MBLY

PRLB

TEAM

TILE

Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday

ADMA Biologics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NYSE">ADMA</a>) short percent of float has risen 37.52% since its last report. The company recently reported that it has 17.08 million shares sold short, which is 7.55% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.81 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>ADMA Biologics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729624521_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ADMA Biologics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing ADMA Biologics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ADMA Biologics's peer group average for short interest as a percentage of float is 15.05%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(ADMA) - Analyzing ADMA Biologics's Short Interest

Throughout the last three months, 4 analysts have evaluated ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $19.0, a high estimate of $20.00, and a low estimate of $18.00. Witnessing a positive shift, the current average has risen by 20.63% from the previous average price target of $15.75.
<img src="https://www.benzinga.com/files/images/story/2024/1728907258_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of ADMA Biologics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to ADMA Biologics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of ADMA Biologics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for ADMA Biologics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into ADMA Biologics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADMA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ADMA Biologics analyst ratings.</a>
<h2>Unveiling the Story Behind ADMA Biologics</h2>
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
<h3>Financial Milestones: ADMA Biologics's Journey</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: ADMA Biologics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 78.29%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: ADMA Biologics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 29.91% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): ADMA Biologics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 18.75% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 8.82%, the company showcases effective utilization of assets.
Debt Management: ADMA Biologics's debt-to-equity ratio surpasses industry norms, standing at 0.75. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From ADMA Biologics Analyst Ratings

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) with a Buy and maintains $18 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on ADMA Biologics, Maintains $18 Price Target

When asked about CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) on CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said, &#8220;I think <a href="https://www.benzinga.com/topic/pharmacy">there's real value here</a>.&#8221;
On Oct. 10, Barclays analyst Andrew Mok upgraded CVS Health from Equal-Weight to Overweight and raised the price target from $63 to $82.
Cramer also recommends buying Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), saying it had an &#8220;<a href="https://www.benzinga.com/quote/MU">amazing&#8221; quarter</a>.
On Oct. 8, Keybanc analyst John Vinh maintained Micron Technology with an Overweight and lowered the price target from $145 to $135.
Although Cramer believes Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) will have a good year, but he prefers the stock of Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>).
On Oct. 9, Citigroup analyst Ariel Rosa initiated coverage on Old Dominion Freight Line with a Neutral rating and announced a price target of $206.
The &#8220;Mad Money&#8221; host recommended not touching American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>).
On Oct. 10, Barclays analyst Tim Long maintained American Tower with an Overweight and raised the price target from $223 to $255.
Cramer said Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) is going higher, adding that it is one of the greatest stocks of his time.
Howmet Aerospace will announce its third quarter 2024 financial results on Wednesday, Nov. 6.
ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) is a &#8220;very speculative&#8221; stock, Cramer said.
On Sept. 20, Cantor Fitzgerald analyst Kristen Kluska reiterated ADMA Biologics with an Overweight and maintained a $20 price target.
Cramer recommended buying Modine Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>). &#8220;It's just one of these great metal-bending companies,&#8221; he added.
On Sept. 24, DA Davidson analyst Matt Summerville maintained Modine Manufacturing with a Buy and raised the price target from $140 to $155.
Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) is a buy, Cramer said.
On Oct. 8, Piper Sandler analyst Patrick Moley maintained Robinhood with an Overweight and maintained a $27 price target.
Price Action:
<ul>
<li>Old Dominion shares gained 0.1% to settle at $194.59 on Thursday.</li>
<li>Micron shares gained 3.9% to close at $105.69.</li>
<li>American Tower shares fell 1.3% to close at $217.90 on Thursday.</li>
<li>Howmet Aerospace shares fell 1.5% to close at $102.10 during the session.</li>
<li>Modine Manufacturing shares fell 2.3% to settle at $130.95 on Thursday.</li>
<li>ADMA Biologics shares fell 16.3% to settle at $17.01.</li>
<li>Robinhood shares fell 0.6% to close at $25.50 on Thursday.</li>
<li>CVS shares gained 1.3% to close at $66.85 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41272079/top-2-health-care-stocks-that-are-ticking-portfolio-bombs">Top 2 Health Care Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Image: Shutterstock

Long Ideas

HOOD

ODFL

CVS Has 'Real Value,' Jim Cramer Says: Micron Had An 'Amazing' Quarter

<h3>Gainers</h3>
<ul>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock rose 20.0% to $0.65 during Thursday's regular session. The market value of their outstanding shares is at $11.2 million. </li>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) shares increased by 18.88% to $2.14. The company's market cap stands at $5.5 million. </li>
<li>NexGel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGL#NASDAQ">NXGL</a>) stock increased by 17.65% to $2.82. The market value of their outstanding shares is at $17.8 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock rose 17.01% to $1.41. The company's market cap stands at $84.8 million. </li>
<li>Genenta Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTA#NASDAQ">GNTA</a>) shares increased by 15.81% to $6.5. The company's market cap stands at $118.4 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares moved upwards by 13.69% to $5.98. The company's market cap stands at $77.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) stock declined by 64.2% to $0.07 during Thursday's regular session. The market value of their outstanding shares is at $8.3 million. </li>
<li>10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) stock fell 25.21% to $15.57. The company's market cap stands at $1.8 billion. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 21.17% to $0.4. The market value of their outstanding shares is at $2.2 million. </li>
<li>ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) stock declined by 19.46% to $16.37. The market value of their outstanding shares is at $3.8 billion. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) shares decreased by 17.78% to $1.11. The company's market cap stands at $27.9 million. </li>
<li>Indivior (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) stock fell 17.27% to $7.81. The company's market cap stands at $1.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GNTA

GRTS

HCTI

INDV

NXGL

RNAZ

Tempest Therapeutics, Inc. - Common Stock

TPST

VCNX

12 Health Care Stocks Moving In Thursday's Intraday Session

Legal

Press Releases

ADMA STOCK REPORT: ADMA Biologics Investors are Notified to Contact BFA Law about the Securities Fraud Investigation after Stock Drops 20%

ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update

ADMA INVESTOR NEWS: ADMA Biologics Investors with Losses May have been Affected by Fraud; Contact BFA Law (Nasdaq:ADMA)

ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law Firm

Kirby McInerney LLP Reminds ADMA Biologics, Inc. (ADMA) Investors of Shareholder Investigation

ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA

ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility

ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025

ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update

Comments

ADMA Biologics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga